Glucobay is the first-line treatment in type 2 diabetes.
EASD 2008
Rome, Italy, hosted this year’s European Association for the Study of Diabetes (EASD) Congress, 7–11 Sept. 2008. This international congress provided an exciting opportunity for Bayer Schering Pharma (BSP) and Bayer Diabetes Care (DC) to join forces, symbolising Bayer HealthCare’s dedication to “Connecting Innovative Strategies in Diabetes Management”.
more 
ESC Congress 2008
More than 30,000 visitors from all parts of the globe gathered in Munich for this year’s ESC (European Society of Cardiology) Congress in Munich (Aug. 30 –Sept. 3), one of the most important cardiology Congress in the world. And of course, Bayer Schering Pharma (a founding father of the conference and major sponsor) was more than represented.
more
ACE (AcarboseCardiovascular Evaluation) anticipates recent US recommendations
With their latest announcements two US expert panels recently attracted some attention amongst the medical community worldwide. And both are indirectly linked to the ACE (AcarboseCardiovascular Evaluation) study what makes them even more interesting.
more
WCPD 2008 - Fighting the Fatal Progression from Diabetes to Heart Disease
At the 5th World Congress on Prevention of Diabetes and its Complications (WCPD), leading experts discussed the need for integrated strategies to combat the “deadly duo” of diabetes and cardiovascular disease (CVD) at the symposium “Preventing diabetes and cardiovascular disease – entering a new era with acarbose”, chaired by Professor Jaakko Tuomilehto, Public Health Department, University of Helsinki, Finland.
more
Glucobay® – the most extensively investigated and widely prescribed α-glucosidase inhibitor – reduces post prandial plasma glucose excursions by delaying the absorption of carbohydrate from the small intestine. Glucobay® is an effective first-line therapy for patients with newly diagnosed type 2 diabetes, and induces a further improvement in glycemic control when used in combination with other antidiabetes agents.
It is therefore a convenient and effective long-term option for the treatment of type 2 diabetes, with a potential added benefit of reducing cardiovascular risk (Hanefeld et al. Eur Heart J 2004).
An effective glycemic control and compliance are critical in patients with type 2 diabetes to prevent disease progression and to reduce the risk of cardiovascular and other complications. In addition to information on Glucobay®, this website provides some material and services that may be helpful for you to improve patient education for a better compliance.
|
